### **Overview** Biocon Ltd, headquartered in Bengaluru, India, is a leading global biopharmaceutical company focused on developing and delivering affordable, high-quality therapies for chronic and high-burden diseases. Through its vertically integrated “lab-to-market” model, the company operates via three core business verticals: - **Biocon Limited:** Focused on affordable generic APIs and finished dosage forms. - **Biocon Biologics Limited (BBL):** A fully integrated global biosimilars company. - **Syngene International:** A contract research, development, and manufacturing organization (CRDMO). Collectively, these units position Biocon as a diversified global healthcare innovator with significant scale, technical excellence, and a mission-driven approach to accessibility. --- ### **Key Highlights (Recent Developments – 2025)** #### **1. Strategic Expansion into the $144 Billion ‘Diabesity’ Market** - In **FY25**, Biocon launched **generic Liraglutide** (branded as **Liraglutide Biocon** for diabetes and **Biolide** for chronic weight management) in the **UK**, making it the **first global company to commercialize a generic GLP-1 therapy** in a major regulated market. - The launch followed **MHRA approval (Jul 2024)** and **Decentralized Procedure (DCP) approvals in the EU**, enabling access across key European markets. - Biocon now holds **exclusive regulatory first-mover status** in the GLP-1 space, with plans for **U.S. launch of gLiraglutide in FY26**. - **Peptides and GLP-1s are now core strategic focus areas**. The company has established **end-to-end manufacturing infrastructure**, including **proprietary delivery devices** and **dedicated peptide facilities in Bengaluru**, positioning itself for long-term leadership. #### **2. Biosimilars Leadership & Commercial Scale** - **Biocon Biologics (BBL)** serves **over 6.0 million patients globally** across **120+ countries**, making it one of the **top 5 global biosimilars players** and the **third-largest producer of recombinant human insulin and Insulin Glargine**. - **U.S. FDA Milestones:** - **Interchangeable approval for biosimilar Insulin Aspart (Kirsty™)** — making Biocon the **only company globally with two interchangeable biosimilar insulins (Glargine and Aspart)** approved in the U.S. - **Interchangeable designation for Semglee® (bGlargine)** has already driven significant market share gains in the U.S. insulin market. - **New Product Launch:** - **YESINTEK™ (ustekinumab biosimilar)** launched in the U.S., EU, Japan, and key markets, achieving **strong physician adoption and broad formulary coverage**. - The fastest “lab-to-market” biosimilar development to date, enabled by innovative parallel clinical trials. - **Oncology Growth:** - Doubled **U.S. market share** for **Fulphila® (bPegfilgrastim)** and **Ogivri® (bTrastuzumab)**. - U.S. FDA approved **Jobevne™ (bBevacizumab)** in April 2025, expanding cancer treatment access. - BBL has **8 biosimilars approved in the U.S. and 7 in Canada**, with a **pipeline of 20 assets**, including high-potential mAbs and insulins. #### **3. Global Manufacturing and Capacity Expansion** - **Malaysia Facility Expansion:** - **Production capacity doubled** for **both drug substance and drug product**, strengthening supply for U.S. and emerging markets. - The site now serves as a **Center of Excellence (CoE)** for insulin manufacturing. - **New U.S. Fill-Finish Facility:** - A **20,000-liter commercial-scale, plug-and-play fill-finish facility** is scheduled to become operational in **FY26**, enhancing product availability and market responsiveness. - **Syngene’s U.S. Acquisition:** - Syngene acquired a **biologics manufacturing facility in Baltimore, Maryland**, adding **multiple monoclonal antibody production lines** and increasing **total single-use bioreactor capacity to 50,000 liters**. - This marks a key step in establishing **trans-Atlantic commercial supply continuity**. - **API & Formulations Infrastructure:** - Operates **five API facilities** (Bengaluru, Hyderabad, Visakhapatnam) and **1,400+ metric tons of annual API manufacturing capacity**. - A **new injectables facility under construction in Bengaluru** will support **pre-filled syringes, pens, and autoinjectors**. #### **4. Regulatory and Approval Milestones (2025)** - **78 product launches** (biosimilars + generics) in FY25. - Over **260 regulatory filings** and **130+ approvals**, including: - **EU DCP approval** for **gLiraglutide**. - **U.S. Tentative Approvals** for **Dasatinib** and **Lenalidamide** (in oncology). - **Final U.S. FDA approvals** for **Insulin Aspart (interchangeable)** and **Bevacizumab (Jobevne™)**. - **VOLUNTARY ACTION INDICATED (VAI)** status from U.S. FDA for facilities in India and Malaysia, enabling faster future approvals. - **155+ APIs and formulations** in portfolio, serving **780+ global customers**, reaching **15.4M patients**. #### **5. Growth Drivers & Strategic Focus Areas** - **‘Diabesity’ Platform:** - **GLP-1 Pipeline:** Actively progressing **Semaglutide and Tirzepatide** through **EU approvals and U.S. filings**, targeting the **$144 billion GLP-1 market by 2029**. - Collaborations with **Zentiva (Europe)** and **Civica Inc. (U.S.)** for expanded access. - **Generics Business Growth:** - **Generic formulations revenue grew from $100M (FY24) to $125M (FY25)**. - **22 generic formulations** commercialized in the U.S.; **five in Europe**. - Focused on **complex formulations**, including **HPAPIs, injectables, peptides, and oncology**, leveraging **vertical integration** for competitive advantage. - **Oncology Expansion:** - Launched **Dasatinib and Lenalidomide** in the U.S., expanding presence in **multiple myeloma and leukemia**. - Multiple biosimilars in advanced markets include **bevacizumab, trastuzumab, adalimumab, and etanercept**. - **Biosimilars Roadmap:** - Plans for **three global and five U.S. biosimilar launches in 2–3 years**, including **bAflibercept, bDenosumab, and bAspart**. #### **6. R&D and Innovation** - **R&D Spend:** Over **$1 billion invested in biosimilars R&D** to date. - **Team:** More than **450–500 scientists** dedicated to biosimilars R&D, supported by **300+ active patents**. - **Proprietary Platforms:** Utilizes **Pichia pastoris** for insulin biosimilars and **mammalian cell culture** for mAbs. - **Syngene’s Innovation:** - **Next-gen protein production platform** to accelerate **mAb, ADC, and recombinant protein development**. - Partners with **Amgen, BMS, Baxter**, and others via **dedicated research centers**. - Invests heavily in **AI-driven drug discovery, data sciences, and Industry 4.0 digitization**. #### **7. Syngene: From CRO to Global CRDMO** - A key growth pillar with **~2 million sq. ft** of R&D and manufacturing infrastructure across **Bengaluru, Hyderabad, Mangaluru, and Baltimore**. - Offers **integrated services** from **early discovery to commercial manufacturing**. - Serves **400+ clients**, including **14 of the top 20 pharma firms**. - **Global CDMO Market Position:** - **Small Molecule CDMO market**: ~$99B (2023) → projected $137B by 2028. - **Large Molecule CDMO market**: ~$22B → expected $39B by 2028. - Syngene acquired **Stelis Biopharma** and launched a **biologics fill-finish unit**, tripling biomanufacturing scale. #### **8. Strategic Acquisitions & Integrations** - **Viatris Biosimilars Integration:** - Acquisition completed ahead of schedule (**by Jul 2024**) across **120+ countries**. - Created a **fully integrated, global biosimilars enterprise** with direct presence in **U.S., EU, Canada, and key emerging markets**. - BBL surpassed **$1 billion in annual revenue in FY24**, becoming **Biocon Group’s largest revenue contributor**. #### **9. Commercial Strategy & Market Presence** - **Multi-Channel Global Reach:** - **Direct operations:** 21 advanced and key emerging markets. - **Partnerships:** With **Sandoz, Abbott, Lupin, Serum Institute, Zentiva, Civica, Tabuk, Farmanguinhos**. - **B2B Collaborations:** In **LATAM, MENA, APAC**, and **Eastern Europe**. - Strong presence in **U.S. (20% patient share), Europe, Brazil, Malaysia**, with **leading market shares**. #### **10. Financial and ESG Outlook** - Issued an **$800 million benchmark bond on the Singapore Exchange**, enhancing **liquidity and financial stability**. - **Regulatory track record:** Over **125 cGMP approvals** from major agencies (FDA, EMA, Health Canada). - Committed to **sustainable manufacturing** with **Industry 4.0 automation, MES, QMS, carbon reduction**, and **solvent recycling initiatives**.